Nobuaki Kobayashi

List of Publications by Year in Descending Order

32 papers	86 citations	5 h-index	7 g-index
34 ext. papers	129 ext. citations	3 avg, IF	2.36 L-index

#	Paper	IF	Citations
32	Immunohistochemical markers to diagnose primary squamous cell carcinoma of the lung: a meta-analysis of diagnostic test accuracy.. *Therapeutic Advances in Medical Oncology*, **2022**, 14, 17588359211065152	5.4	
31	Adverse events induced by nivolumab and ipilimumab combination regimens.. *Therapeutic Advances in Medical Oncology*, **2022**, 14, 17588359211058393	5.4	3
30	Decline in mortality due to respiratory diseases in Japan during the coronavirus disease 2019 pandemic. *Respirology*, **2021**,	3.6	1
29	The Extent of Honeycombing on Computed Tomography Cannot Predict the Treatment Outcome of Patients with Acute Exacerbations of Interstitial Lung Disease. *Canadian Respiratory Journal*, **2021**, 2021, 7456315	2.1	
28	Clinical Features and Risk Factors for Mortality in Hospitalized Older Adults with Pneumonia. *Canadian Respiratory Journal*, **2021**, 2021, 5644824	2.1	
27	Comparison of Clinical Features between the High and Low Serum KL-6 Patients with Acute Exacerbation of Interstitial Lung Diseases. *Canadian Respiratory Journal*, **2021**, 2021, 9099802	2.1	
26	Best regimens for treating chemo-naïve incurable squamous non-small cell lung cancer with a programmed death-ligand 1 tumor proportion score of 1%-49%: A network meta-analysis. *Thoracic Cancer*, **2021**,	3.2	1
25	Diagnostic utility of transbronchial biopsy for Hodgkin's lymphoma: A case study. *Thoracic Cancer*, **2021**, 12, 3281-3285	3.2	1
24	ABO blood group as a risk factor for tuberculosis: A network meta-analysis. *International Journal of Infectious Diseases*, **2021**, 104, 701-707	10.5	1
23	T-cell response to phytohemagglutinin in the interferon-γ release assay as a potential biomarker for the response to immune checkpoint inhibitors in patients with non-small cell lung cancer. *Thoracic Cancer*, **2021**, 12, 1726-1734	3.2	3
22	Real-world evaluation of a computed tomography-first triage strategy for suspected Coronavirus disease 2019 in outpatients in Japan: An observational cohort study. *Medicine (United States)*, **2021**, 100, e26161	1.8	2
21	Effect of coexisting advanced extrapulmonary solid cancer on progression of Mycobacterium avium complex lung disease. *Jornal Brasileiro De Pneumologia*, **2021**, 47, e20200520	1.1	1
20	Resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer patients: A meta-analysis. *Thoracic Cancer*, **2021**, 12, 1096-1105	3.2	6
19	Severe anaphylaxis caused by intravenous anti-cancer drugs. *Cancer Medicine*, **2021**, 10, 7174-7183	4.8	1
18	Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non-small-cell lung cancer: A multicenter retrospective trial. *Thoracic Cancer*, **2021**,	3.2	1
17	Afatinib + bevacizumab combination therapy in EGFR-mutant NSCLC patients with osimertinib resistance: Protocol of an open-label, phase II, multicenter, single-arm trial. *Thoracic Cancer*, **2020**, 11, 2125-2129	3.2	2
16	The clinical significance of CXCL16 in the treatment of advanced non-small cell lung cancer. *Thoracic Cancer*, **2020**, 11, 1258-1264	3.2	5

List of Publications

15	Pembrolizumab-induced secondary sclerosing cholangitis in a non-small cell lung cancer patient. *Respirology Case Reports*, **2020**, 8, e00560	0.9	5
14	Identification of Biomarkers for Non-small-cell Lung Cancer Patients Treated With an Immune Checkpoint Inhibitor. *Anticancer Research*, **2020**, 40, 3889-3896	2.3	7
13	Class A CpG oligodeoxynucleotide inhibits IFN-β-induced signaling and apoptosis in lung cancer. *Thoracic Cancer*, **2020**, 11, 983-992	3.2	1
12	MicroRNA-200b is a potential biomarker of the expression of PD-L1 in patients with lung cancer. *Thoracic Cancer*, **2020**, 11, 2975-2982	3.2	5
11	Identification of a novel biomarker based on lymphocyte count, albumin level, and TBAg/PHA ratio for differentiation between active and latent tuberculosis infection in Japan. *Tuberculosis*, **2020**, 125, 101992	2.6	5
10	Systematic review of first-line chemotherapy for chemo-naïve extensive-stage small-cell lung cancer: network meta-analysis. *Therapeutic Advances in Medical Oncology*, **2020**, 12, 1758835920965841	5.4	5
9	Unusual lung involvements of invasive mucinous adenocarcinoma with chylothorax. *Thoracic Cancer* , **2020**, 11, 3407-3408	3.2	
8	Reproducibility of the T-SPOT.TB test for screening Mycobacterium tuberculosis infection in Japan. *Journal of Infection and Chemotherapy*, **2020**, 26, 194-198	2.2	2
7	Non-small cell lung cancer with mesenchymal-epithelial transition gene exon 14 skipping mutation treated with crizotinib. *Respirology Case Reports*, **2019**, 7, e00453	0.9	3
6	Hepcidin exerts a negative immunological effect in pulmonary tuberculosis without HIV co-infection, prolonging the time to culture-negative. *International Journal of Infectious Diseases*, **2019**, 86, 47-54	10.5	1
5	Computed tomography imaging-based observation of the aggressive growth of angiosarcoma: a case study. *Respirology Case Reports*, **2019**, 7, e00479	0.9	1
4	The Platelet Count Can Predict In-hospital Death in HIV-negative Smear-positive Pulmonary Tuberculosis Inpatients. *Internal Medicine*, **2018**, 57, 1391-1397	1.1	7
3	HbA1c level cannot predict the treatment outcome of smear-positive non-multi-drug-resistant HIV-negative pulmonary tuberculosis inpatients. *Scientific Reports*, **2017**, 7, 46488	4.9	
2	Factors for Predicting Outcomes among Non-HIV Patients with Pulmonary Tuberculosis. *Internal Medicine*, **2017**, 56, 3277-3282	1.1	5
1	Oligodeoxynucleotides expressing polyguanosine motifs promote antitumor activity through the upregulation of IL-2. *Journal of Immunology*, **2013**, 190, 1882-9	5.3	11